A multicenter study has developed a predictive model to help identify pancreatic cancer patients who are unlikely to benefit from surgery after neoadjuvant therapy. The research focuses on pancreatic ductal adenocarcinoma patients who receive chemotherapy before surgery. Although this approach can improve outcomes, about 24% of patients still experience very poor results after surgery, with […]
A Phase 2 study shows that combining PDS01ADC, an IL-12 immunotherapy agent, with hepatic artery infusion pump (HAIP) chemotherapy may significantly improve outcomes for patients with metastatic colorectal cancer that has spread to the liver. The combination aims to both directly attack liver tumors and stimulate the immune system. PDS01ADC helps activate immune responses against
The combination of darlifarnib with cabozantinib may overcome treatment resistance in advanced clear cell renal cell carcinoma. The study tested a “re-challenge” approach, where darlifarnib helps tumors respond again to cabozantinib, even in patients who had previously progressed on the same drug. This suggests a new way to extend the usefulness of existing therapies. In
Combination Therapy Reverses Drug Resistance in Advanced Kidney Cancer Read More »
Interim results show promising activity for rezatapopt (PC14586) in patients with advanced ovarian cancer carrying the TP53 Y220C mutation. Rezatapopt is a first-in-class oral drug designed to restore the function of the mutated p53 protein, a key tumor suppressor. By stabilizing this specific mutation, the drug helps cancer cells regain normal growth control, offering a
Rezatapopt Shows Strong Response in TP53-Mutant Ovarian Cancer in Phase 2 Trial Read More »
A new mathematical model explains how living systems maintain order and resist disorder. The model views genes as active agents rather than static instructions. They produce enzymes that guide chemical reactions efficiently and steer them toward useful outcomes, helping cells stay organized. It also highlights how proteins consistently fold into precise 3D shapes despite many
New Model Suggests Restoring Cell Communication Could Redefine Cancer Treatment Read More »
Researchers have identified a promising new blood test that may help detect colorectal cancer using a specialized protein called SubB2M to measure a sugar molecule known as Neu5Gc. The test addresses limitations of current screening methods. Colonoscopies are effective but invasive, while stool-based tests can miss early disease. Existing blood markers such as CEA and
New SubB2M Blood Test Shows High Accuracy for Early Detection of colorectal cancer Read More »
The FDA has granted Orphan Drug Designation to eftilagimod alfa for the treatment of soft tissue sarcoma, supporting its development with incentives such as tax credits and market exclusivity if approved. Eftilagimod alfa works by activating antigen-presenting cells and strengthening both innate and adaptive immune responses. It boosts CD8+ T cells that help the immune
The phase 3 AFFIRM-205 trial shows that the combination of afuresertib and fulvestrant significantly improves outcomes in patients with advanced HR-positive HER2-negative breast cancer with PIK3CA/AKT1/PTEN pathway alterations. Many of these patients had already developed resistance after prior treatments, including CDK4/6 inhibitors. The study met its main goal, showing that the combination delayed disease progression
The EZH2 inhibitor mevrometostat is moving into phase 3 trials as a potential treatment for metastatic castration-resistant prostate cancer after encouraging early results. The approach targets EZH2, an epigenetic regulator that helps cancer cells become more aggressive and resistant to treatment, including androgen receptor pathway inhibitors like enzalutamide. In a phase 1 study, combining mevrometostat
Real-world data and circulating tumor DNA (ctDNA) are helping doctors detect and overcome treatment resistance in EGFR-mutated non-small cell lung cancer. Resistance patterns vary by treatment. With osimertinib alone, common causes include MET amplification and secondary EGFR mutations. In combination therapy, such as osimertinib plus chemotherapy, resistance can also involve small cell transformation. Newer combinations